Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Founded Year



Secondary Market | Dead

Total Raised


About EntoMed

Developer of medicines derived from the immune responses of insects. The company develops medicines targeting life-threatening infections of both fungal and bacterial origin that have become resistant to existing antibiotics and antifungal drugs. The company has identified biologically important classes of peptides and small molecules, and has purified and characterised hundreds of antimicrobial compounds that have a broad spectrum of activity against fungi and bacteria. The company has also developed inhouse cancer screening capabilities.

EntoMed Headquarter Location

Rue Tobias Simmer

Illkirch-Graffenstaden, 67400,


33 3 90 40 58 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.